A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

RETROSPECTIVE CHART REVIEW STUDY OF FIRST LINE LORLATINIB IN LOCALLY ADVANCED/METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN CHINA

The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC.

The participants included in this study are:

• Aged 18 years or more
• diagnosed with a/mNSCLC
• confirmed with testing for ALK-positive
• have started first-line lorlatinib treatment during the patient selection period

In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Age ≥18 years
2. Diagnosed with a/mNSCLC
3. Confirmed testing for ALK-positive
4. Initiated first-line lorlatinib treatment during the patient selection period, prior therapy such as adjuvant or neoadjuvant treatment are allowed.
5. A minimum lookback period of at least 3 months to establish a baseline period and ensure first-line use of cohort entry drug
6. Have at least 6 months of follow-up data available (early death or progression will be included)